Pomegranate ellagitannin-derived compounds exhibit antiproferative and antiaromatase activity in breast cancer cells In vitro

Cancer Prevention Research

Volumn 3, Issue 1, 2010, Pages 108-113

  Adams, Lynn S ^a   Zhang, Yanjun ^b   Seeram, Navindra P ^b   Heber, David ^b   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE; ELLAGIC ACID; ELLAGITANNIN; ESTROGEN; GALLAGIC ACID; POMEGRANATE EXTRACT; TESTOSTERONE; UNCLASSIFIED DRUG; UROLITHIN A; UROLITHIN B; PLANT EXTRACT; TANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; KINETICS; POMEGRANATE; PRIORITY JOURNAL; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; FEMALE; METABOLISM; TUMOR CELL LINE;

AROMATASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; HYDROLYZABLE TANNINS; PLANT EXTRACTS; PUNICACEAE;

EID: 77649212752     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0225     Document Type: Article

References (24)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-62.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
3. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
4. Morandi P, Rouzier R, Altundag K, et al. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer 2004;101:1482-9.
5. O'Shaughnessy J. A decade of letrozole: FACE. Breast Cancer Res Treat 2007;105 Suppl 1:67-74.
6. Boccardo F, Rubagotti A, Aldrighetti D, et al. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. Cancer 2007;109:1060-7.
7. Seeram NP, Zhang Y, Reed J, Krueger C, Vaya J. Pomegranate Phytochemicals. In: Schulman R, Seeram NP, Heber D, editors. Pomegranates Ancient Roots to Modern Medicine. Boca Raton (FL): Taylor & Francis Group; 2006, p. 3-30.
8. Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005;16:360-7.
9. Adams LS, Seeram NP, Aggarwal BB, et al. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006;54:980-5.
10. Seeram NP, Henning SM, Zhang Y, et al. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136:2481-5.
11. Cerda B, Espin JC, Parra S, Martinez P, Tomas-Barberan FA. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr 2004;43:205-20.
12. Cerda B, Soto C, Albaladejo MD, et al. Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2006;60:245-53.
13. Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L, Derendorf H. Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem 2006;54:8956-61.
14. Seeram NP, Aronson WJ, Zhang Y, et al. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 2007;55:7732-7.
15. Larrosa M, Gonzalez-Sarrias A, Garcia-Conesa MT, Tomas-Barberan FA, Espin JC. Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J Agric Food Chem 2006;54:1611-20.
16. Ghosal SLJ, Singh S, Kumar Y, Shilajit F. Chemistry of two bioactive benzopyrone metabolites. J Chem Res Synop 1989;11:350-1.
17. Sun XZ, Zhou D, Chen S. Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol 1997;63:29-36.
18. Grube BJ, Eng ET, Kao YC, Kwon A, Chen S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr 2001;131:3288-93.
19. Kao YC, Cam LL, Laughton CA, Zhou D, Chen S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res 1996;56:3451-60.
20. Chen S, Kao YC, Laughton CA. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase. J Steroid Biochem Mol Biol 1997;61:107-15.
21. Kao YC, Zhou C, Sherman M, Laughton CA, Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 1998;106:85-92.
22. Chen S, Cho M, Karlsberg K, Zhou D, Yuan YC. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J Biol Chem 2004;279:48071-8.
23. Kim ND, Mehta R, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002;71:203-17.
24. Hong Y, Chen S. Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 2006;1089:237-51.